Like its predecessors in this annual series, offers critical reviews of recent major developments in pharmacology of anti-cancer agents, the area of biologicals, and clinical management of the cancer patient. Nine contributions in the first section discuss drugs--antimetabolites, alkylating agents, bleomycin, mitomycins, taxanes, DNA topoisomerase inhibitors, cisplatin, and multidrug resistance. The following seven contributions discuss biological response modifiers--monoclonal antibody therapy, cytokines and immunological monitoring, adoptive immunotherapy, gene therapy, hematopoietic growth factors, reference databases of cytokine structure and function. The third section comprises 14 contributions on various kinds of tumors.
Annotation c. Book News, Inc., Portland, OR (booknews.com)